Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

MESALAMINE

MESALAMINE

Standard Dose
400MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview MESALAMINE is listed in Drugs@FDA under application 207873 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient MESALAMINE Form and strength CAPSULE, DELAYED RELEASE;ORAL - 400MG Sponsor TEVA PHARMS USA Submission history Latest submission status date: 2025-03-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview MESALAMINE is listed in Drugs@FDA under application 207873 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient MESALAMINE Form and strength CAPSULE, DELAYED RELEASE;ORAL - 400MG Sponsor TEVA PHARMS USA Submission history Latest submission status date: 2025-03-06 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.